Halken S, et al. - By pooling data from 9 double-blinded, randomized European or North American trials, researchers evaluated the short- as well as long-term tolerability and safety of timothy grass sublingual immunotherapy (SLIT)-tablets in children, given these tablets are suggested for children suffering from allergic rhinitis with or without conjunctivitis (AR/C). Data were pooled from children with AR/C managed up to 3 years with once-daily timothy grass SLIT-tablet or placebo. The study included 1,818 (SLIT-tablet = 923; placebo = 895) participants. Findings revealed good tolerability of short- and long-term timothy grass SLIT-tablet in children, irrespective of the geographic region. The reported adverse events (AEs) included transient allergic reactions, and AEs were generally local and mild.